• On 27 June 2026, Stoke Therapeutics, Inc. was removed from several Russell indices, including the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Benchmark, reflecting updated index reconstitution decisions.
• This broad index removal can meaningfully alter the company’s investor base and trading patterns as index-linked funds rebalance their holdings.
• We’ll now examine how Stoke Therapeutics’ removal from multiple Russell indices may influence its existing investment narrative and risk profile.

Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.

Stoke Therapeutics Investment Narrative Recap

To own Stoke Therapeutics today, you need to believe that zorevunersen can eventually clear Phase III and regulatory hurdles and become a meaningful treatment for Dravet syndrome, while STK 002 extends the platform into ADOA over time. The Russell index removals may affect trading and liquidity but do not directly change the scientific, clinical, or regulatory catalysts, nor the key risks around EMPEROR outcomes, payer access, or long term safety.

In this context, the March 2026 New England Journal of Medicine publication of zorevunersen Phase 1/2a and open label extension data is especially important. It anchors the current disease modifying narrative with multi year seizure and cognition findings and supports the design of the EMPEROR Phase III trial, which remains central to both the upside case and the concern that controlled data may not fully reproduce earlier open label results.

Yet while the story can sound straightforward, there is an important risk investors should be aware of if EMPEROR fails to confirm the earlier seizure and cognition benefits and...

Stoke Therapeutics' narrative projects $177.8 million revenue and $33.6 million earnings by 2029. This requires 77.0% yearly revenue growth and a $203.4 million earnings increase from -$169.8 million today.

Uncover how Stoke Therapeutics' forecasts yield a $45.10 fair value, a 41% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already modeling a 50.0% annual revenue decline and a tiny US$4.4 million profit by 2029, so after the Russell removals you should expect that this more pessimistic camp, which also worries that EMPEROR setbacks could reset approval expectations, may update their view very differently from those focused mainly on the trial’s upside potential.

Explore 3 other fair value estimates on Stoke Therapeutics - why the stock might be worth over 9x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Stoke Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Stoke Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stoke Therapeutics' overall financial health at a glance.

Ready For A Different Approach?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 51 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.